OpenSourceMalaria:GSK Arylpyrrole Series: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
Line 78: Line 78:
A new class of antimalarial was recently published by Novartis, [http://dxd.doi.org/10.1021/jm2003359 Imidazolopiperazines].
A new class of antimalarial was recently published by Novartis, [http://dxd.doi.org/10.1021/jm2003359 Imidazolopiperazines].


Misc papers to digest/assimilate regarding antimycobacterial/tuberculosis activity: [http://dx.doi.org10.1021/jm701560p Antimycobacterial 1,5-diphenyl pyrroles], [http://dx.doi.org/10.1016/j.ejmech.2009.06.005 10.1016/j.ejmech.2009.06.005], [http://dx.doi.org/10.1016/j.bmc.2010.09.006], [http://dx.doi.org/10.1002/cmdc.201000526 10.1002/cmdc.201000526]<br>
Misc papers to digest/assimilate regarding antimycobacterial/tuberculosis activity: [http://dx.doi.org10.1021/jm701560p Antimycobacterial 1,5-diphenyl pyrroles], [http://dx.doi.org/10.1016/j.ejmech.2009.06.005 10.1016/j.ejmech.2009.06.005], [http://dx.doi.org/10.1016/j.bmc.2010.09.006 10.1016/j.bmc.2010.09.006], [http://dx.doi.org/10.1002/cmdc.201000526 10.1002/cmdc.201000526]<br>


'''Scifinder Search:'''
'''Scifinder Search:'''

Revision as of 16:29, 28 November 2011

Malaria Home        OSM So Far        Compound Series        Links        Open Source Research Home        Tech Ops        FAQ       


The Arylpyrrole Series

The initial two leads have the general structure:

GSK Tres Cantos Arylpyrrole Generic Structure

These compounds are currently under study by the Todd lab at the University of Sydney and the Medicines for Malaria Venture, Geneva. As an open source project, anyone may participate:
Coordination/Discussion site
Electronic Lab Notebooks
Compounds are commercially-available
Series was listed as one of the most promising leads from TCAMS set (though lacking aryl F)

A number of these compounds and intermediates are available for biological testing from Todd group by request.

The two known series examples

TCMDC 123812

TCMDC123812

InChI=1/C15H15FN2O3/c1-9-7-13(15(20)21-8-14(17)19)10(2)18(9)12-5-3-11(16)4-6-12/h3-7H,8H2,1-2H3,(H2,17,19)
SMILES: O=C(N)COC(=O)c2c(n(c1ccc(F)cc1)c(c2)C)C
CAS Registry Number: 733026-12-5
Chemspider page
ChEMBL Page
Resynthesis:

TCMDC 123794

TCMDC123794

InChI=1/C26H25FN4O4/c1-16-14-22(17(2)30(16)20-12-10-19(27)11-13-20)26(34)35-15-23(32)28-24-18(3)29(4)31(25(24)33)21-8-6-5-7-9-21/h5-14H,15H2,1-4H3,(H,28,32)
SMILES: Fc1ccc(cc1)n2c(cc(c2C)C(=O)OCC(=O)NC=4C(=O)N(c3ccccc3)N(C=4C)C)C
Chemspider page
ChEMBL Page
Resynthesis:

The proposed resynthesis strategy for these two compounds:

Proposed Synthesis Strategy

Known "Near Neighbours" contained in the Tres Cantos set

Known GSK Arylpyrrole Near Neighbours


Data/links for these compounds:

TCMDC-123563, CHEMBL546966, CHEMBL page: 637010 Cc1ccc(cc1)n2c(cc(c2C)C(=O)CN3C(=O)C(NC3=O)Cc4ccccc4)C

TCMDC-125698, CHEMBL587989, CHEMBL: 627784 Cc1cc(c(n1c2ccc(cc2)Cl)C)C=C3C(=O)N(C(=Nc4ccccc4)S3)C5CCCC5

TCMDC-125697, CHEMBL581336, CHEMBL: 640978 CCOC(=O)c1ccc(cc1)n2c(cc(c2C)C=C3C(=O)N(C(=Nc4ccccc4)S3)C5CCCC5)C

TCMDC-125659, CHEMBL528140, CHEMBL: 626220 Cc1ccnc(c1)n2c(cc(c2C)C=C3C(=O)N(C(=Nc4ccccc4)S3)Cc5ccco5)C

TCMDC-124103, CHEMBL588465, CHEMBL: 643107 Cc1cc(cc(c1)n2c(cc(c2C)C=C3C(=O)NC(=Nc4ccc(cc4)Cl)S3)C)C

TCMDC-124456, CHEMBL548395, CHEMBL: 640006 CCn1c(cc(c1C)C=C2C(=O)NC(=Nc3ccccc3)S2)C

Potential synthesis strategy toward near-neighbours

Current synthesis toward near neighbours

Experimental information available from PMY 13-1, PMY 14-1 and PMY 16-1, PMY 14-3.

Other known incidences of these molecules/this series

Related compounds are known to inhibit the proteasome, according to this Nature paper.

A new class of antimalarial was recently published by Novartis, Imidazolopiperazines.

Misc papers to digest/assimilate regarding antimycobacterial/tuberculosis activity: Antimycobacterial 1,5-diphenyl pyrroles, 10.1016/j.ejmech.2009.06.005, 10.1016/j.bmc.2010.09.006, 10.1002/cmdc.201000526

Scifinder Search: 2,4,5-alkyl-1-aryl-pyrrole: 77552 hits, 905 biological studies:

WO 2011127333 (A2)

CXCR4 active compound

US 2011251184 (A1)

HDAC6 inhibitor

Obesity/diabetes GIP receptor inhibitor JP 2011184298 (A)

GIP inhibitor

Proteasome WO 2011094545 (A2)

Proteasome agonist

WO2006076202 Steroid nuclear receptor ligands

WO 2011075684 (A1) Inhibitors of Plasma Kallikrein/Protease